Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
Takanori Numata, Jun Araya, Hanae Miyagawa, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 395-405
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
Hiroyuki Nagase, Maho Suzukawa, Keiji Oishi, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 11-23
Open Access | Times Cited: 58
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
Corrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 29
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
Leonard B. Bacharier, Ian Pavord, Jorge Máspero, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 101-110
Closed Access | Times Cited: 15
Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study
Tomoko Tajiri, Motohiko Suzuki, Hirono Nishiyama, et al.
Allergology International (2024) Vol. 73, Iss. 3, pp. 406-415
Open Access | Times Cited: 14
Switching Biological Therapies in Severe Asthma
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9563-9563
Open Access | Times Cited: 16
Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study
Takanori Numata, Jun Araya, Keitaro Okuda, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1731-1741
Open Access | Times Cited: 26
Precision medicine for severe asthma – Biological targeted therapy
Bingqing Sun, Kunlu Shen, Ruiheng Zhao, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112189-112189
Open Access | Times Cited: 5
Real-world effectiveness of dupilumab versus benralizumab and mepolizumab
Eugene R. Bleecker, Michael S. Blaiss, Juby A. Jacob‐Nara, et al.
Allergy and Asthma Proceedings (2024) Vol. 45, Iss. 4, pp. 219-231
Closed Access | Times Cited: 5
Biologics in severe asthma: a state-of-the-art review
Bishal Gyawali, Steve N. Georas, Sandhya Khurana
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240088-240088
Open Access
Analysis and mining of Dupilumab adverse events based on FAERS database
Gao Hui, Liqiang Cao, Chengying Liu
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Biologics for severe asthma and beyond
Carlo Mümmler, Katrin Milger
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108551-108551
Closed Access | Times Cited: 9
Personalized Medicine in Severe Asthma: From Biomarkers to Biologics
Chun‐Yu Chen, Kang‐Hsi Wu, Bei-Cyuan Guo, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 182-182
Open Access | Times Cited: 9
Combination Biologic Therapy with Mepolizumab and Dupilumab for Severe Eosinophilic Granulomatosis with Polyangiitis and Chronic Rhinosinusitis with Nasal Polyp
Yosuke Nakamura, Naoki Kikumoto, Hiromi Takeuchi, et al.
Yonago acta medica (2024) Vol. 67, Iss. 2, pp. 157-162
Open Access | Times Cited: 3
How Can Dupilumab Cause Eosinophilic Pneumonia?
Momoko Kurihara, Katsunori Masaki, Emiko Matsuyama, et al.
Biomolecules (2022) Vol. 12, Iss. 12, pp. 1743-1743
Open Access | Times Cited: 14
Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry
Rebecca Gall, Neal Jain, Weily Soong, et al.
Advances in Therapy (2023) Vol. 40, Iss. 3, pp. 1292-1298
Open Access | Times Cited: 8
Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study
Hisao Higo, Hirohisa Ichikawa, Yukako Arakawa, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 16, pp. 5174-5174
Open Access | Times Cited: 7
Time effect of dupilumab to treat severe uncontrolled asthma in adolescents
Cristiana Indolfi, Giulio Dinardo, Angela Klain, et al.
Allergologia et Immunopathologia (2023) Vol. 51, Iss. 5, pp. 12-18
Open Access | Times Cited: 7
Advancing Care in Severe Asthma: The Art of Switching Biologics
Silvano Dragonieri, Andrea Portacci, Vitaliano Nicola Quaranta, et al.
Advances in respiratory medicine (2024) Vol. 92, Iss. 2, pp. 110-122
Open Access | Times Cited: 2
Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study
Lotte Bult, John C. Thelen, Simone P. Rauh, et al.
Respiratory Medicine (2024) Vol. 231, pp. 107720-107720
Open Access | Times Cited: 2
Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study
Koichi Fukunaga, Etsuko Tagaya, Masato Ishida, et al.
Allergology International (2023) Vol. 72, Iss. 4, pp. 537-544
Open Access | Times Cited: 5
Changes in Peripheral Blood Eosinophil Counts and Risk of Eosinophilic Granulomatosis with Polyangiitis Onset after Initiation of Dupilumab Administration in Adult Patients with Asthma
Yoshitomo Kushima, Yasuo Shimizu, H Hoshi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5721-5721
Open Access | Times Cited: 4
Real-world effectiveness of dupilumab in patients with asthma
Michael S. Blaiss, Eugene R. Bleecker, Juby A. Jacob‐Nara, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 4, pp. 463-468.e1
Closed Access | Times Cited: 4
Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis
María Basagaña, Carlos Martínez‐Rivera, Clara Padró, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 1
Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met?
E Villamañán, Daniel Laorden, Paula Granda, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7152-7152
Open Access | Times Cited: 1
Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma
İnsu Yılmaz, Gülden Paçacı Çetin, Bahar Arslan, et al.
Tuberkuloz ve Toraks (2023) Vol. 71, Iss. 1, pp. 75-93
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top